Table 6

Linear regression for the decline in eGFR in the entire DHS cohort and in participants without and with prevalent diabetes according to SMg per 0.2 mg/dL decrease

	Model 1			Model 2			Model 3			Model 4			Model 5
	β	95% CI	P value	β	95% CI	P value	β	95% CI	P value	β	95% Cl	P value	β	95% CI	P value
Entire cohort	− 0.40	0.53 to -0.25	<0.001	− 0.34	0.49 to −0.19	<0.001	− 0.31	0.47 to −0.16	<0.001	− 0.30	–0.44 to -0.14	<0.001	− 0.23	0.38 to -0.08	0.003
Without prevalent DM	− 0.24	0.39 to −0.09	0.001	− 0.22	0.37 to -0.06	0.008	− 0.21	0.36 to −0.05	0.01	− 0.18	–0.34 to −0.02	0.02	–	–	–
With prevalent DM	− 0.78	1.31 to -0.24	0.005	− 0.58	1.16 to −0.002	0.05	− 0.60	1.20 to −0.01	0.05	− 0.51	–1.09 to 0.08	0.09	–	–	–

Model 1 was adjusted for age, gender, race/ethnicity, body mass index at DHS-1.
Model 2 was adjusted for variables in model 1 plus serum phosphorus, calcium, bicarbonate, albumin, intact parathyroid hormone, total cholesterol and high-density lipoprotein at DHS-1.
Model 3 was adjusted for variables in model 2 plus use of diuretics, dietary supplements, ACEI and ARB at DHS-1.
Model 4 was adjusted for variables in model 3 plus prevalent hypertension and CRP at DHS-1.
Model 5 was adjusted for variables in model 4 plus prevalent type 2 diabetes at DHS 1.
β, change in eGFR in reference to the highest quintile of SMg levels. eGFR was calculated according to the MDRD study equation. ΔeGFR was calculated as eGFR at DHS-2 minus eGFR at DHS-1.
ACEI, ACE inhibitors; ARB, angiotensin II receptor blockers; CRP, C reactive protein; DHS, Dallas Heart Study; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; SMg, serum magnesium.